Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged
The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer wa...
- Autores:
-
Arias Murillo, Yazmin Rocio
Salinas Nova, Maria Angelica
Caicedo, Tatiana
Galindo-Borda, Marisol
Meneses-Gil, Ximena
Montero, Camilo
Giron, Fernando
Pedraza, Nestor
Aroca-Martinez, Gustavo
Ospina-Martínez, Martha Lucía
Mercado-Reyes, Marcela
- Tipo de recurso:
- Fecha de publicación:
- 2024
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/15724
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/15724
https://doi.org/10.1016/j.transproceed.2023.02.034
https://www.sciencedirect.com/science/article/pii/S0041134523000696?via%3Dihub
- Palabra clave:
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivs 3.0 United States
| id |
USIMONBOL2_d0264dfdb4b543d8e5279d4d5a85bc6a |
|---|---|
| oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/15724 |
| network_acronym_str |
USIMONBOL2 |
| network_name_str |
Repositorio Digital USB |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| title |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| spellingShingle |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| title_short |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| title_full |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| title_fullStr |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| title_full_unstemmed |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| title_sort |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged |
| dc.creator.fl_str_mv |
Arias Murillo, Yazmin Rocio Salinas Nova, Maria Angelica Caicedo, Tatiana Galindo-Borda, Marisol Meneses-Gil, Ximena Montero, Camilo Giron, Fernando Pedraza, Nestor Aroca-Martinez, Gustavo Ospina-Martínez, Martha Lucía Mercado-Reyes, Marcela |
| dc.contributor.author.none.fl_str_mv |
Arias Murillo, Yazmin Rocio Salinas Nova, Maria Angelica Caicedo, Tatiana Galindo-Borda, Marisol Meneses-Gil, Ximena Montero, Camilo Giron, Fernando Pedraza, Nestor Aroca-Martinez, Gustavo Ospina-Martínez, Martha Lucía Mercado-Reyes, Marcela |
| description |
The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with Corona- Vac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment. |
| publishDate |
2024 |
| dc.date.accessioned.none.fl_str_mv |
2024-10-01T16:05:04Z |
| dc.date.available.none.fl_str_mv |
2024-10-01T16:05:04Z |
| dc.date.issued.none.fl_str_mv |
2024 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.spa.none.fl_str_mv |
Artículo científico |
| dc.identifier.issn.none.fl_str_mv |
00411345 (Impreso) 18732623 (Electrónico) |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/15724 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.transproceed.2023.02.034 |
| dc.identifier.url.none.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0041134523000696?via%3Dihub |
| identifier_str_mv |
00411345 (Impreso) 18732623 (Electrónico) |
| url |
https://hdl.handle.net/20.500.12442/15724 https://doi.org/10.1016/j.transproceed.2023.02.034 https://www.sciencedirect.com/science/article/pii/S0041134523000696?via%3Dihub |
| dc.language.iso.none.fl_str_mv |
eng |
| language |
eng |
| dc.rights.eng.fl_str_mv |
Attribution-NonCommercial-NoDerivs 3.0 United States |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/3.0/us/ |
| dc.rights.accessrights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivs 3.0 United States http://creativecommons.org/licenses/by-nc-nd/3.0/us/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.none.fl_str_mv |
pdf |
| dc.publisher.eng.fl_str_mv |
Elsevier |
| dc.source.eng.fl_str_mv |
Transplantation Proceedings |
| dc.source.spa.fl_str_mv |
Vol. 55 No. 3 Año 2023 |
| institution |
Universidad Simón Bolívar |
| bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/8640e723-20ef-4284-b761-0de806ddc716/download https://bonga.unisimon.edu.co/bitstreams/427b877f-b70f-4c50-9a75-c0c2e84d3ba4/download https://bonga.unisimon.edu.co/bitstreams/55b2e48b-8f0f-4fbc-9dc1-e9bb29021b40/download https://bonga.unisimon.edu.co/bitstreams/2e15ad10-6649-4548-ad97-1513341ee586/download https://bonga.unisimon.edu.co/bitstreams/b3bd3e9c-c0f8-4466-ba2c-ab7a384f0b5d/download |
| bitstream.checksum.fl_str_mv |
788a79f32fbe1cc40b08e53000f9b869 2f656a26de8af8c32aaacd5e2a33538c 733bec43a0bf5ade4d97db708e29b185 8b234379dddba98c014a227c0f551da7 2ccafadd6e5e30690fbf10c8028c9b72 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
| repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
| _version_ |
1812100487420313600 |
| spelling |
Arias Murillo, Yazmin Rocio0e6422d6-60d9-4fc8-b92b-47c829e413fa600Salinas Nova, Maria Angelica7d7290a2-ad67-43d6-bbed-134b707bfcde600Caicedo, Tatiana743025da-908f-4376-b208-6e78b3d582a3-1Galindo-Borda, Marisol4d516cca-b759-474d-887f-1ac48f878c5e-1Meneses-Gil, Ximena44e3006a-5948-44ab-a3f3-9ab74a33ef44-1Montero, Camilo065b8673-a76b-4053-a2c0-8cebf5e98c94-1Giron, Fernandob27b4925-6fae-4f94-bb29-3249748b9142-1Pedraza, Nestor7a1d7ad2-c87e-40c2-ac44-eec38624e493600Aroca-Martinez, Gustavo9ebd2f8e-91b1-462f-a15a-09db2a45ce2b600Ospina-Martínez, Martha Lucía6bf92bb7-1918-4a05-a8b1-4aeed1e28b37-1Mercado-Reyes, Marcela4051c239-53db-43d2-8387-89d8d2d814e2-12024-10-01T16:05:04Z2024-10-01T16:05:04Z202400411345 (Impreso)18732623 (Electrónico)https://hdl.handle.net/20.500.12442/15724https://doi.org/10.1016/j.transproceed.2023.02.034https://www.sciencedirect.com/science/article/pii/S0041134523000696?via%3DihubThe huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with Corona- Vac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment.pdfengElsevierAttribution-NonCommercial-NoDerivs 3.0 United Stateshttp://creativecommons.org/licenses/by-nc-nd/3.0/us/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Transplantation ProceedingsVol. 55 No. 3 Año 2023Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstagedinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20:1800–8.TagedEndAkalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med 2020;382:2475–7.TagedEndArias-Murillo YR, Benavides-V CA, Salinas-N MA, Osorio- Arango K, Plazas-Sierra C, Cort es JA. SARS-CoV2/COVID-19 infection in transplant recipients and patients on the transplant waiting list in Colombia. Transplant Proc 2021;53:1237–44.TagedEndMagicova M, Zahradka I, Fialova M, et al. Determinants of immune response to anti-SARS-CoV-2 mRNA vaccines in kidney transplant recipients: a prospective cohort study. Transplantation 2022;106:842–52.TagedEndSanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation 2022;106:821–34.TagedEndBenotmane I, Gautier-Vargas G, Cognard N, et al. Weak anti- SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int 2021;99:1487–9.Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204–6.TagedEndRozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect 2021;27(1173):e1–.e4.TagedEndBenotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int 2021;99:1498– 500.TagedEndHaskin O, Ashkenazi-Hoffnung L, Ziv N, et al. Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients. Transplantation 2021;105:e226–33.Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant 2021;21:2727–39.TagedEndBalcells ME, Le Corre N, Dur an J, et al. Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile. Clin Infect Dis 2022;75:e594–602.TagedEndMiele M, Bus a R, Russelli G, et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant 2021;21:2919–21.Marinaki S, Adamopoulos S, Degiannis D, et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am J Transplant 2021;21:2913–5.TagedEndGrupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021;21:2719–26.TagedEndHall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant 2021;21:3980–9.TagedEndRössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARSCoV- 2 omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med 2022;386:698–700.Eren Sadioglu R, Demir E, Evren E, et al. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients. Transpl Infect Dis 2021;23:e13740.Dheir H, Tocoglu A, Toptan H, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidneytransplant patients. J Med Virol 2022;94: 3176–83.TagedEndMariana S, Florencia R, Jose S, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidneytransplant patients. Clin Kidney J 2022;15: 527–33.TagedEndBruminhent J, Setthaudom C, Chaumdee P, et al. SARS-CoV- 2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study). Am J Transplant 2022;22:813–22.TagedEndSeija M, Rammauro F, Santiago J, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidney transplant patients. Clin Kidney J 2022;15: 527–33.TagedEndCorreia AL, Leal R, Pimenta AC, et al. The type of SARSCoV- 2 vaccine influences serological response in kidney transplant recipients. Clin Transplant 2022;36:e14585.TagedEndPrendecki M, Thomson T, Candice L, et al. Willicombe M in collaboration with the OSC. Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. medRxiv, in press.Gangappa S, Wrammert J, Wang D, et al. Kinetics of antibody response to influenza vaccination in renal transplant recipients. Transpl Immunol 2019;53:51–60.TagedEndOu MT, Boyarsky BJ, Chiang TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking Belatacept. Transplantation 2021;105:2119–23.Chavarot N, Ouedrani A, Marion O, et al. Poor anti-SARSCoV- 2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with Belatacept. Transplantation 2021;105:e94–5.TagedEndAbravanel F, Marion O, Del Bello A, et al. Humoral and cellular immune responses of solid organ transplant patients on Belatacept to three doses of mRNA-based anti-SARS-CoV-2 vaccine. Vaccines (Basel) 2022;10:354.TagedEndNoble J, LangelloA, Bouchut W, Lupo J, Lombardo D, Rostaing L. Immune response post−SARS-CoV-2 mRNA vaccination in kidney transplant recipients receiving Belatacept. Transplantation 2021;105:e259–60.Hammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med 2022;386:1221–9.ORIGINALPDF.pdfPDF.pdfapplication/pdf765247https://bonga.unisimon.edu.co/bitstreams/8640e723-20ef-4284-b761-0de806ddc716/download788a79f32fbe1cc40b08e53000f9b869MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8905https://bonga.unisimon.edu.co/bitstreams/427b877f-b70f-4c50-9a75-c0c2e84d3ba4/download2f656a26de8af8c32aaacd5e2a33538cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/55b2e48b-8f0f-4fbc-9dc1-e9bb29021b40/download733bec43a0bf5ade4d97db708e29b185MD53TEXTPDF.pdf.txtPDF.pdf.txtExtracted texttext/plain43403https://bonga.unisimon.edu.co/bitstreams/2e15ad10-6649-4548-ad97-1513341ee586/download8b234379dddba98c014a227c0f551da7MD54THUMBNAILPDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5790https://bonga.unisimon.edu.co/bitstreams/b3bd3e9c-c0f8-4466-ba2c-ab7a384f0b5d/download2ccafadd6e5e30690fbf10c8028c9b72MD5520.500.12442/15724oai:bonga.unisimon.edu.co:20.500.12442/157242024-10-02 03:02:20.049http://creativecommons.org/licenses/by-nc-nd/3.0/us/Attribution-NonCommercial-NoDerivs 3.0 United Statesopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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 |